Table 1.

Summary of clinical data.

Case #	Cytoar. area	Age (year/s)	Major symptom(s)	Pathology	Drug/daily dose/duration (days)1
HBC 961102a	46	59/M	Left hemiparesis	Frontal metastasis from lung carcinoma	Phenobarbital/100 mg/10
HBC 970105a,b	32	56/F	High intracranial pressure	Hemorrhage from capsulostriatal, cavernoma	Phenobarbital/100 mg/35
HBC 980510b,c,d,e	46	60/M	High intracranial pressure	Frontal meningioma	Valproate/1000 mg/30
HBC 980611b,c,d,e	10	64/F	High intracranial pressure	Orbito-frontal meningioma	Valproate/1000 mg/30
HBC 981114d	21	65/M	Absent	Temporal fossa meningioma	Phenobarbital/100 mg/14
HBC 981115	10	64/M	Anosmia	Orbito-frontal meningioma	Phenobarbital/100 mg/21
HBC 981219c,d,e	9	60/F	Absent	Frontal metastasis from breast cancer	Phenobarbital/100 mg/30, dexamethasone 16 mg/14
HBC 030129	8	64/M	High intracranial pressure	Frontal meningioma	Valproate/1000 mg/30
HBC 040925d,e	7	58/F	Visual field defect	Parasagittal meningioma	Oxcarbazepine/900 mg/2
HBC 050230	7	37/F	Absent	Paraventricular, meningioma	Oxcarbazepine/900 mg/15, dexamethasone 16 mg/15
HBC 050231	8	80/F	High intracranial pressure	Hemorrhagic stroke	None
HBC 070532	19	64/F	Absent	Parasagittal meningioma	Oxcarbazepine/900 mg/2
HBC 070533	10	49/F	Left hemiparesis	Basal nuclei glioma	Oxcarbazepine/900 mg/10, dexamethasone 16 mg/10

¹Drugs used in perisurgical prophylactic therapy.

^a–eCases used in previous studies: ^aConti et al. (1998); ^bConti et al. (1999); ^cMelone et al. (2004); ^dMelone et al. (2005a); ^eMelone et al. (2006).